Business
CASTLE BIOSCIENCES INC: We may need to raise additional capital to fund our existing operations, commercialize new products or expand our operations.
Revenue increased 3.7% to $344.2M, while Net income decreased 232.4% to ($24.2M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $344.2MWatch
- Profitability — Net income ($24.2M)Watch
- Cash generation — Free cash flow $28.3MOK
- Accounting — Formula-grey distress score · no manipulation flag · earnings quality safeNote
- Insiders — 0 buys; 47 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as CASTLE BIOSCIENCES INC reports it. History and quarterly detail are in the app.
- Dermatologic$216.4M
- Non Dermatologic$127.9M
Leadership changes
From CASTLE BIOSCIENCES INC's own filings, the day they're filed.
- Rodney Cotton · director · appointmenteff. 2024-03-26
- Mara G. Aspinall · Directors · departureeff. 2024-03-26
- Good Reason · departure
Latest filings
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-05-29
- 10-Q · Quarterly report2026-05-06
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CASTLE BIOSCIENCES INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.